Eric Yaovi Mesan A.
- Country
- France
- Department
- Medical Oncology
Research Overview
- Phase 3 Study of Vepugratinib and Combination Therapy in Adults with Untreated FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
- Phase III Evaluation of Acetylsalicylic Acid and Atorvastatin on Overall Survival in Castration-Resistant Prostate Cancer Patients
- Evaluation of Talazoparib and Enzalutamide Efficacy in Metastatic Castration-Resistant Prostate Cancer Post-Abiraterone Progression
Data & Insights
Has run more than one trial at 85 of 313 partner sites.
Specializations
Breast Cancer and Hormone Receptor-Driven Malignancies
Clinical research activity includes ER-positive, HER2-negative, and HER2-positive breast cancer, with attention to locally advanced, metastatic, and early-stage disease. The portfolio also extends to triple-negative breast cancer, ESR1-mutated disease, and settings defined by PIK3CA or BRCA alterations.
- Advanced breast cancer
- Endocrine-resistant disease
- HER2-low and HER2-positive subtypes
- Triple-negative breast cancer
Interest also covers treatment-resistant and biomarker-defined breast cancer populations, including recurrence prevention and post-endocrine therapy strategies.
Genitourinary Cancers
Research involvement is strong in prostate cancer, renal cell carcinoma, urothelial carcinoma, and bladder cancer, with emphasis on advanced, metastatic, and recurrence-prone disease. The therapeutic landscape includes castration-resistant prostate cancer, hormone-sensitive prostate cancer, and renal malignancies with clear cell and non-clear cell histology.
- Metastatic prostate cancer
- Renal cell carcinoma
- Urothelial and bladder cancers
- Biomarker-selected genitourinary tumors
Work also includes disease states linked to homologous recombination repair defects and other molecularly defined genitourinary subsets.
Gynecologic and Gynecologic Oncology
Clinical trial activity spans ovarian cancer, endometrial carcinoma, cervical cancer, vulvar cancer, and related fallopian tube and peritoneal malignancies. The therapeutic focus includes recurrent, platinum-resistant, and high-risk disease as well as tumors with HER2, FGFR2b, or folate receptor-alpha expression.
- Ovarian and fallopian tube cancers
- Endometrial and cervical cancers
- Platinum-resistant disease
- Molecularly selected gynecologic tumors
Interest also extends to recurrent carcinosarcoma and advanced gynecologic cancers requiring targeted or immunotherapy-based approaches.
Thoracic, Head and Neck, and Upper Gastrointestinal Cancers
Research activity includes non-small cell lung cancer, small cell lung cancer, mesothelioma, head and neck squamous cell carcinoma, esophageal cancer, and gastric or gastroesophageal junction adenocarcinoma. The portfolio reflects interest in locally advanced, unresectable, recurrent, and metastatic disease across these sites.
- Lung cancer
- Head and neck squamous cell carcinoma
- Esophageal and gastric cancers
- Mesothelioma
Work also includes biomarker-driven thoracic and upper gastrointestinal tumors, particularly in settings involving PD-L1 expression and actionable molecular alterations.
Pediatric Solid Tumors and Sarcomas
Clinical interest covers sarcoma subtypes, gastrointestinal stromal tumor, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, and selected pediatric brain tumors. The therapeutic scope includes refractory and relapsed disease, as well as rare and molecularly defined tumor entities.
- Soft tissue and bone sarcomas
- Gastrointestinal stromal tumor
- Neuroblastoma and pediatric solid tumors
- Diffuse midline glioma and related CNS tumors
Research also spans pediatric and adolescent oncology settings where targeted therapy and immunotherapy are being explored for difficult-to-treat solid tumors.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.